Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments

Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments

Abstract Trastuzumab (TZM) is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and is clinically used for the treatment of HER2‐positive breast tumors. However, the tumor microenvironment can limit the access of TZM to the HER2 targets across the whole tumor and...

Full description

Saved in:
Bibliographic Details
Main Authors: Amit Verma, Vikas Pandey, Catherine Sherry, Taylor Humphrey, Christopher James, Kailie Matteson, Jason T. Smith, Alena Rudkouskaya, Xavier Intes, Margarida Barroso
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Advanced Science
Subjects:
breast tumor
fluorescence lifetime imaging
FRET
HER2
Trastuzumab
target engagement
Online Access:https://doi.org/10.1002/advs.202403253
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202403253

Similar Items